North of Tyne, Gateshead and North Cumbria Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on **Tuesday 27th April 2021.**

Classification of products:

R = 'RED' drugs for hospital use only
A = 'AMBER' drugs suitable for use under Shared Care arrangements
G+ = 'GREEN PLUS – Drugs normally recommended or initiated by hospital specialist, but where the provision of an information leaflet may be appropriate to facilitate continuing treatment by GPs. Many of these information sheets are in the process of development.
G = 'GREEN' – Drugs where initiation by GPs is appropriate.

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meetings				
None				
2) New Requests				
None				
3) New formulations & extensions to use				
Oxycodone m/r (OxyPro®)	✓ G			Significant savings are to be made by changing first line modified release oxycodone from Longtec® to OxyPro®. This work is being explored elsewhere in the ICS area and the committee agreed to endorse such a move. Pain and palliative care clinicians in the relevant organisations will need to be involved in the process, as well as primary care. **Decision:** OxyPro® to replace Longtec® as the first line formulary choice from 1/10/21
Dexamethasone 20mg/5ml	✓ R			Haematologists at Northumbria have requested to use the higher dose liquid, 20mg/5ml, to ease the pill burden. **Decision:** Approved. The 20mg/5ml liquid will be added to the formulary as a RED drug for patients requiring high doses.
Dulaglutide (Trulicity) 3mgs and 4.5mgs	✓ G			Request received to add Dulaglutide (Trulicity) 3mgs and 4.5mgs alongside the 0.75mg and 1.5 mg strengths already on formulary to allow dosing flexibility. **Decision:** Approved

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
4) NHS England Specialised Services communications noted and endorsed by APC				
SSC2210 NICE Technology Appraisal Final Appraisal Determination: niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy.				The formulary will reflect the SSC position
SSC2211 NICE Technology Appraisal Final Appraisal Determination: KTE-X19 (Tecartus®) for treating relapsed or refractory mantle cell lymphoma.				The formulary will reflect the SSC position
SSC2212 Early Access to Medicines Scheme – nivolumab in combination with ipilimumab for the first line treatment of adult patients with unresectable malignant pleural mesothelioma (MPM).				The formulary will reflect the SSC position
SSC2226 Early Access to Medicines Scheme – pemigatinib in the treatment of adults with locally advanced or metastatic cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that is relapsed or refractory after at least one line of systemic therapy				The formulary will reflect the SSC position
SSC2228 Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy				The formulary will reflect the SSC position
SSC2236: NICE Technology Appraisal - acalabrutinib for treating chronic lymphocytic leukaemia				The formulary will reflect the SSC position
SSC2237 NICE Technology Appraisal Final Appraisal Determination - Pembrolizumab for previously treated advanced or metastatic urothelial cancer				The formulary will reflect the SSC position
SSC2238 NICE Technology Appraisal Final Appraisal Determination - olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer.				The formulary will reflect the SSC position
SSC2239 NICE Technology Appraisal Final Appraisal Determination - carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma.				The formulary will reflect the SSC position
SSC2240 NICE Technology Appraisal Final Appraisal Determination: avelumab for untreated metastatic Merkel cell carcinoma.				The formulary will reflect the SSC position
5) Products considered by NICE				
TA670 Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor				The formulary will reflect the NICE position
TA 671 Mepolizumab for treating severe eosinophilic asthma Update and replacement for NICE TA 431				The formulary will reflect the NICE position
TA672 Brolucizumab for treating wet age-related macular degeneration				The formulary will reflect the NICE position
TA673 Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy				The formulary will reflect the NICE position
TA676 Filgotinib for treating moderate to severe rheumatoid arthritis				The formulary will reflect the NICE position
TA677 Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma				The formulary will reflect the NICE position
TA679 Dapagliflozin for treating chronic heart failure with reduced ejection fraction				The formulary will reflect the NICE position

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
TA680 Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma				The formulary will reflect the NICE position
TA681 Baricitinib for treating moderate to severe atopic dermatitis				The formulary will reflect the NICE position
TA682 Erenumab for preventing migraine				The formulary will reflect the NICE position
TA683 Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer				The formulary will reflect the NICE position
TA684 Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease				The formulary will reflect the NICE position
TA685 Anakinra for treating Still's disease				The formulary will reflect the NICE position
TA687 Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy				The formulary will reflect the NICE position
TA689 Acalabrutinib for treating chronic lymphocytic leukaemia				The formulary will reflect the NICE position
TA691Avelumab for untreated metastatic Merkel cell carcinoma				The formulary will reflect the NICE position
HST14 Metreleptin for treating lipodystrophy - highly specialised technologies				The formulary will reflect the NICE position
6) Northern (NHS) Treatment Advisory Group (N-TAG)				
Flash Glucose Monitoring - update				The formulary will reflect the N – TAG position
Teriparatide for atypical bisphosphonate induced fractures				The formulary will reflect the N – TAG position
Doxylamine/Pyridoxine (Xonvea®)				The formulary will reflect the N – TAG position
7) Regional Medicines Optimisation Committee (RMOC) – guidance noted				
Shared care guidance				"Shared Care for Medicines Guidance – A Standard Approach"
Buprenorphine guidance				https://www.sps.nhs.uk/wp-content/uploads/2021/04/RMOC-Buprenorphine-guidance-Final-V1.0.pdf This guidance informs local decision-making processes but the FSC will still need to consider applications for use in our area.
8) Appeals against earlier decisions by the APC				
None				
9) Guidelines approved/retired. http://www.northoftyneapc.nhs.uk/guidance/				
SPS NOAC table	Retired as link is included in the AF guidance			
Naltrexone guidance	Retired			
Preterm infant feeding	Approved			
Faltering growth	Approved			
Gender dysphoria	The guideline will be hosted on the regional services website. The APC website will include a link to this.			
Adult ADHD	Approved			
CMPA	Expiry date extended by one year			
Renal disease	Expiry date extended to December 2021			
10) Miscellaneous decisions by the APC				

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
Hydroxychloroquine				The RCOP monitoring guidelines were updated in November 2020 and now recommend eye monitoring should only be carried out after 5 years unless there are other specific risk factors or baseline eye problems. **Decision:** The committee endorsed a status change for hydroxychloroquine from GREEN PLUS to AMBER to ensure appropriate long term follow up. A shared care agreement will be required.
Valproate - Pregnancy Prevention Programme (PPP)				Audit work shows poor compliance in the Pregnancy Prevention Programme (PPP) and valproate. **Decision**: The committee endorsed a status change for valproate in women of childbearing age from GREEN PLUS to AMBER to ensure appropriate long term follow up. A shared care agreement will be required.
Ulipristal 5mg tablets (Esmya®)				Change to formulary status required in relation to ulipristal due to a change in licence. Use will be restricted to intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women who have not reached menopause when uterine fibroid embolisation and/or surgical treatment options are not suitable. Decision: Ulipristal 5mg tablet status change to RED